Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023)
Revolution Medicines (RVMD) recorded quarterly EBITDA Margin of 21579.78% in Q4 2023, down 658.49% quarter-over-quarter from 2845.11% in Q2 2023, and down 2117726.0% on a YoY basis from N/an in Q4 2022.
Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023) Analysis & Trends
Revolution Medicines' EBITDA Margin history runs 5 years deep, the most recent figure standing at 21579.78% for Q4 2023.
- In Q4 2023, EBITDA Margin fell 2117726.0% year-over-year to 21579.78%; the TTM figure through Sep 2024 stood at 81972.64% (down 8062093.0% YoY), while the FY2023 annual figure was 3748.21%, down 304129.0% from the prior year.
- EBITDA Margin was 21579.78% for Q4 2023 at Revolution Medicines, down from 2845.11% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 79.26% in Q1 2019 to a low of 21579.78% in Q4 2023.
- Historically, EBITDA Margin has averaged 1968.35% across 5 years, with a median of 402.52% in 2022.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin soared 254813 bps in 2022, then sank 2117726 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 161.85% in 2019, then sank by 141 bps to 389.44% in 2020, then plunged by 44 bps to 559.33% in 2021, then increased by 28 bps to 402.52% in 2022, then slumped by 5261 bps to 21579.78% in 2023.
- The last three EBITDA Margin figures came in at 21579.78% (Q4 2023), 2845.11% (Q2 2023), and 1071.53% (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Revolution Medicines | 32.33 Bn | 32.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -21,579.78% |
| Jun 30, 2023 | -2,845.11% |
| Mar 31, 2023 | -1,071.53% |
| Dec 31, 2022 | -402.52% |
| Sep 30, 2022 | -2,280.48% |
| Jun 30, 2022 | -681.10% |
| Mar 31, 2022 | -764.70% |
| Dec 31, 2021 | -559.33% |
| Sep 30, 2021 | -4,828.61% |
| Jun 30, 2021 | -512.01% |
| Mar 31, 2021 | -369.13% |
| Dec 31, 2020 | -389.44% |
| Sep 30, 2020 | -217.61% |
| Jun 30, 2020 | -279.14% |
| Mar 31, 2020 | -182.59% |
| Dec 31, 2019 | -161.85% |
| Sep 30, 2019 | -108.42% |
| Jun 30, 2019 | -85.99% |
| Mar 31, 2019 | -79.26% |